Outcome prediction in patients with glioblastoma by using imaging, clinical, and genomic biomarkers: Focus on the nonenhancing component of the tumor

Radiology

Volumn 272, Issue 2, 2014, Pages 484-493

  Jain, Rajan ^a,j   Poisson, Laila M ^a   Gutman, David ^b   Scarpace, Lisa ^a   Hwang, Scott N ^c   Holder, Chad A ^b   Wintermark, Max ^d   Rao, Arvind ^e   Colen, Rivka R ^e,f   Kirby, Justin ^g   Freymann, John ^g   Jaffe, C Carl ^h   Mikkelsen, Tom ^a   Flanders, Adam ⁱ  

^a HENRY FORD HEALTH SYSTEM   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g SAIC FREDERICK INC   (United States)

^h BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^j NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; AGE DISTRIBUTION; ARTICLE; BRAIN BLOOD VOLUME; BRAIN SURGERY; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISEASE MARKER; FEMALE; GENE MUTATION; GENETIC CORRELATION; GENOME ANALYSIS; GLIOBLASTOMA; HUMAN; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL PREDICTION; SURVIVAL TIME; WHITE MATTER;

BRAIN NEOPLASMS; CONTRAST MEDIA; FEMALE; GENOMICS; GLIOBLASTOMA; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

EID: 84905046756     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.14131691     Document Type: Article

References (40)

1. Scherer HJ. The forms of growth in gliomas and their practical significance. Brain 1940;63(1):1-35.
2. Burger PC, Heinz ER, Shibata T, Kleihues P. Topographic anatomy and CT correlations in the untreated glioblastoma multiforme. J Neurosurg 1988;68(5):698-704.
3. Parsa AT, Wachhorst S, Lamborn KR, et al. Prognostic significance of intracranial dissemination of glioblastoma multiforme in adults. J Neurosurg 2005;102(4):622-628. (Pubitemid 43186665)
4. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010;28(11):1963-1972.
5. Chamberlain MC. Radiographic patterns of relapse in glioblastoma. J Neurooncol 2011;101(2):319-323.
6. Dobelbower MC, Burnett Iii OL, Nordal RA, et al. Patterns of failure for glioblastoma multiforme following concurrent radiation and temozolomide. J Med Imaging Radiat Oncol 2011;55(1):77-81.
7. McDonald MW, Shu HK, Curran WJ Jr, Crocker IR. Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma. Int J Radiat Oncol Biol Phys 2011;79(1):130-136.
8. Cha S, Knopp EA, Johnson G, Wetzel SG, Litt AW, Zagzag D. Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging. Radiology 2002;223(1):11-29. (Pubitemid 34258186)
9. Law M, Cha S, Knopp EA, Johnson G, Arnett J, Litt AW. High-grade gliomas and solitary metastases: differentiation by using perfusion and proton spectroscopic MR imaging. Radiology 2002;222(3):715-721. (Pubitemid 34215219)
10. Chiang IC, Kuo YT, Lu CY, et al. Distinction between high-grade gliomas and solitary metastases using peritumoral 3-T magnetic resonance spectroscopy, diffusion, and perfusion imagings. Neuroradiology 2004;46(8):619-627. (Pubitemid 39199519)
11. Lu S, Ahn D, Johnson G, Law M, Zagzag D, Grossman RI. Diffusion-tensor MR imaging of intracranial neoplasia and associated peritumoral edema: introduction of the tumor infiltration index. Radiology 2004;232(1):221-228. (Pubitemid 38787841)
12. Price SJ, Gillard JH. Imaging biomarkers of brain tumour margin and tumour invasion. Br J Radiol 2011;84(Spec No 2):S159-S167.
13. Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001;95(2):190-198. (Pubitemid 32799739)
14. Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008;62(4):753-764; discussion 264-266.
15. Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 2011;115(1):3-8.
16. Aldave G, Tejada S, Pay E, et al. Prognostic value of residual fluorescent tissue in glioblastoma patients after gross total resection in 5-aminolevulinic acid-guided surgery. Neurosurgery 2013;72(6):925-920; discussion 920-921.
17. Cancer Imaging Program via the Cancer Imaging Archive (TCIA) Web site. http://cancerimagingarchive.net/. Published November 22, 2013. Accessed February 26, 2014.
18. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455(7216):1061-1068. [Published correction appears in Nature 2013;494(7438):506.]
19. Jain R, Poisson L, Narang J, et al. Genomic mapping and survival prediction in glioblastoma: molecular subclassification strengthened by hemodynamic imaging biomarkers. Radiology 2013;267(1):212-220.
20. Gutman DA, Cooper LA, Hwang SN, et al. MR imaging predictors of molecular profile and survival: multi-institutional study of the TCGA glioblastoma data set. Radiology 2013;267(2):560-569.
21. Cancer Biomedical Informatics Grid. Clearcanvas with the AIM plugin. National Cancer Institute Web site. https://gforge.nci.nih.gov. Accessed December 28, 2011.
22. New AS, Hazlett EA, Newmark RE, et al. Laboratory induced aggression: a positron emission tomography study of aggressive individuals with borderline personality disorder. Biol Psychiatry 2009;66(12):1107-1114.
23. Channin DS, Mongkolwat P, Kleper V, Rubin DL. The Annotation and Image Mark-up project. Radiology 2009;253(3):590-592.
24. Channin DS, Mongkolwat P, Kleper V, Sepukar K, Rubin DL. The caBIG annotation and image Markup project. J Digit Imaging 2010;23(2):217-225.
25. Rubin DL, Mongkolwat P, Channin DS. A semantic image annotation model to enable integrative translational research. Summit on Translat Bioinforma 2009;2009:106-110.
26. Vasari MRI Visual Feature Guide. The Cancer Imaging Archive (TCIA) Web site. https://wiki.cancerimagingarchive.net/display/Public/ VASARI+Research+Project. Published April 7, 2010. Accessed June 11, 2013.
27. Boxerman JL, Schmainda KM, Weisskoff RM. Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. AJNR Am J Neuroradiol 2006;27(4):859-867. (Pubitemid 44897737)
28. Huse JT, Phillips HS, Brennan CW. Molecular subclassification of diffuse gliomas: seeing order in the chaos. Glia 2011;59(8):1190-1199.
29. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17(1):98-110.
30. Ishwaran H, Kogalur UB. Random survival forests for R. R News 2007;7:25-31.
31. Ishwaran H, Kogalur UB, Blackstone EH, Lauer MS. Random survival forests. Ann Appl Stat 2008;2(3):841-860.
32. Ishwaran H, Kogalur UB. RandomSurvival-Forest: Random Survival Forests. R package version 3.6.3. http://cran.r-project.org/. Published 2010. Accessed February 26, 2014.
33. Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 2000;56(2):337-344. (Pubitemid 30422619)
34. Heagerty PJ, Zheng Y. Survival model predictive accuracy and ROC curves. Biometrics 2005;61(1):92-105. (Pubitemid 40380968)
35. Wang S, Kim S, Chawla S, et al. Differentiation between glioblastomas, solitary brain metastases, and primary cerebral lymphomas using diffusion tensor and dynamic susceptibility contrast-enhanced MR imaging. AJNR Am J Neuroradiol 2011;32(3):507-514.
36. Zinn PO, Mahajan B, Sathyan P, et al. Radiogenomic mapping of edema/cellular invasion MRI-phenotypes in glioblastoma multiforme. PLoS ONE 2011;6(10):e25451.
37. Pope WB, Sayre J, Perlina A, Villablanca JP, Mischel PS, Cloughesy TF. MR imaging correlates of survival in patients with high-grade gliomas. AJNR Am J Neuroradiol 2005;26(10):2466-2474.
38. Schucht P, Beck J, Abu-Isa J, et al. Gross total resection rates in contemporary glioblastoma surgery: results of an institutional protocol combining 5-aminolevulinic acid intraoperative fluorescence imaging and brain mapping. Neurosurgery 2012;71(5):927-935; discussion 935-936.
39. Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 2006;7(5):392-401.
40. Idoate MA, Díez Valle R, Echeveste J, Tejada S. Pathological characterization of the glioblastoma border as shown during surgery using 5-aminolevulinic acid-induced fluorescence. Neuropathology 2011;31(6):575-582.